Emcure Pharmaceuticals Halves Price of Semaglutide Weight Loss Drug Poviztra Following Patent Expiry

Original: Emcure halves price of its semaglutide weight loss drug Poviztra after Novo Nordisk patent expiry — check new rates

Mint•Apr 2, 20263 min

In a Nutshell

Emcure Pharmaceuticals has reduced the price of its semaglutide injection, Poviztra, by 54% to make obesity treatment more accessible. The new monthly price starts at ₹3,999 (approximately $48 USD) and will take effect on April 3, 2026, following the expiration of Novo Nordisk's patent in India.

Key Points

01Emcure has cut the price of Poviztra by 54%, making it more affordable for patients.
02The new starting price is ₹3,999 (approximately $48 USD) per month.
03Price reductions across higher doses average 47%.
04The price cut follows the expiration of Novo Nordisk's patent on semaglutide.
05Analysts predict the semaglutide market in India could reach $1 billion with increased accessibility.

In-Article Ad

Full Summary

Emcure Pharmaceuticals has announced a significant price reduction for its weight management drug Poviztra, a semaglutide injection, cutting the monthly cost from ₹8,790 (approximately $106 USD) to ₹3,999 (approximately $48 USD). This move aims to improve access to obesity treatments in India, where obesity is increasingly recognized as a public health issue. The new pricing will take effect on April 3, 2026, and applies to all dosage strengths, with reductions averaging 47% for higher doses. This announcement follows the expiration of the patent for semaglutide, previously held by Danish pharmaceutical company Novo Nordisk, which has led to a surge in competition as other companies introduce cheaper alternatives. Investment bank Jefferies has highlighted the potential for the semaglutide market in India to reach $1 billion, contingent on effective pricing strategies and patient uptake. Emcure's CEO, Satish Mehta, emphasized that this price revision is a step towards making scientifically validated weight-management therapies accessible to a broader patient base.

Key Figures

₹3,999

New starting price for Poviztra per month

54%

Percentage reduction in the price of Poviztra

$1 billion

Projected market size for semaglutide in India

47%

Average price reduction across higher doses

In-Article Ad

Why It Matters

This price reduction will make weight management treatments significantly more affordable for many patients in India, potentially improving health outcomes related to obesity.

Who is affected

Patients seeking weight management solutions, particularly those previously unable to afford such treatments.

What to know

Patients interested in weight management should consult healthcare providers about the new pricing and availability of Poviztra.

FAQ

The new prices will take effect on April 3, 2026.

The new prices are: 0.25 mg at ₹3,999, 0.5 mg at ₹4,999, 1 mg at ₹5,999, 1.7 mg at ₹7,999, and 2.4 mg at ₹8,999.

✦